EVAX | Evaxion Biotech A/S Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.8836 - 0.9501
52 Week Range	0.8470 - 13.61
Beta	-0.41
Implied Volatility	470.90%
IV Rank	37.12%
Day's Volume	73,293
Average Volume	61,304
Shares Outstanding	5,411,054
Market Cap	49,781,701
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-02-05

Valuation
Profitability
Growth
Health
P/E Ratio	-0.33
Forward P/E Ratio	N/A
EPS	-2.80
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	49
Country	Denmark
Website	EVAX

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

EVAX's peers: SGTX, RVPH, ZVSA, KRBP, UNCY, QNRX, ALLR, VRAX, BDRX, LYEL, CGEM, GLUE, THRX, RVMD, EFTR, LABP, APGN, NAVB, ANGN, REVB, ZURA, PHIO, RNAZ, SNSE

*Chart delayed

Analyzing fundamentals for EVAX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see EVAX Fundamentals page.

Watching at EVAX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on EVAX Technicals page.